ALPN实时信号 | 通过Getagraph.com最大化利润

出售 159 min ago

@ $64.64

发出时间: 29 Apr 2024 @ 21:33

回报率: 0.05%

上一信号: Apr 26 - 00:46

上一信号: 购买

回报率: 0.02 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:10):
Our systems believe the stock currently is overvalued by 1.43% compare to its pairs and should correct downwards.

Stats
今日成交量	579 607
平均成交量	2.21M
市值	4.24B
EPS	$0 ( 2024-03-18 )
下一个收益日期	( $-0.410 ) 2024-06-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-101.04
ATR14	$0.110 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Fuhs Ulrich Martin	Sell	0	Common Stock
2024-04-03	Fuhs Ulrich Martin	Sell	75 000	Stock Option (Right to buy)
2024-04-03	Fuhs Ulrich Martin	Sell	28 700	Stock Option (Right to buy)
2024-04-03	Fuhs Ulrich Martin	Sell	14 600	Stock Option (Right to buy)
2024-01-25	Rickey James Paul	Sell	236	Stock Option (Right to buy)

INSIDER POWER
-21.38
Last 100 transactions
Buy: 4 566 792 \| Sell: 7 050 513

相关性 (AI algo v.1.1b): Overvalued: -1.43% $63.74 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: -0.41 (neutral)

短: -0.63 (weak negative)

Signal:(56) Neutral

Alpine Immune Sciences 相关性

10 最正相关
FCNCA	0.951
IZEA	0.95
SZZL	0.949
MSDA	0.946
BOXL	0.945
VECO	0.945
APYX	0.943
PNNT	0.941
ESQ	0.94
BTWN	0.939

10 最负相关
SILK	-0.944
PAYS	-0.936
AGRI	-0.934
ZSAN	-0.933
PRQR	-0.932
EBET	-0.932
TTCF	-0.931
TCFC	-0.924
IMBI	-0.923
FWBI	-0.919

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alpine Immune Sciences 相关性 - 货币/商品

0.44
( neutral )

0.05
( neutral )

0.00
( neutral )

-0.75
( moderate negative )

-0.35
( neutral )

Alpine Immune Sciences 财务报表

Annual	2023
营收:	$58.88M
毛利润:	$58.30M (99.02 %)
EPS:	$-0.640

FY	2023
营收:	$58.88M
毛利润:	$58.30M (99.02 %)
EPS:	$-0.640

FY	2022
营收:	$30.06M
毛利润:	$29.47M (98.01 %)
EPS:	$-1.730

FY	2021
营收:	$23.44M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.